Related Experiment Video
Updated: Mar 28, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Systemic sclerosis and calcinosis cutis: response to rituximab
H Poormoghim1, E Andalib1, A R Almasi2
1Scleroderma Study Group, Department of Rheumatology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
What Is Known And Objective:
Calcinosis cutis (or cutaneous calcification) is a type of calcinosis wherein calcium deposits form in the skin and frequently encountered in limited cutaneous subtype of disease. So far, no treatment has shown an explicit beneficial effect. Medical therapy for calcinosis cutis with rituximab is limited and of variable benefit.
Case Summary:
Our patient was 54-year-old lady, a case of limited cutaneous scleroderma with widespread progressive calcinosis cutis unresponsive to current therapy. She went under treatment with rituximab with no successful outcome.
What Is New And Conclusion:
Results of therapy with rituximab on regression/improvement of systemic sclerosis-related calcinosis are limited and non-conclusive.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Cardiomyopathy IV: Restrictive Cardiomyopathy
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
